- Home
- WWR vs OCX Comparison
WWR vs OCX Comparison
Compare WWR & OCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WWR
- OCX
- Stock Information
- Founded
- WWR 1977
- OCX 2009
- Country
- WWR United States
- OCX United States
- Employees
- WWR N/A
- OCX N/A
- Industry
- WWR Metal Mining
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- WWR Basic Materials
- OCX Health Care
- Exchange
- WWR Nasdaq
- OCX Nasdaq
- Market Cap
- WWR 45.0M
- OCX 80.1M
- IPO Year
- WWR N/A
- OCX N/A
- Fundamental
- Price
- WWR $0.62
- OCX $4.09
- Analyst Decision
- WWR Strong Buy
- OCX Buy
- Analyst Count
- WWR 1
- OCX 3
- Target Price
- WWR $2.50
- OCX $4.42
- AVG Volume (30 Days)
- WWR 650.3K
- OCX 117.8K
- Earning Date
- WWR 03-25-2025
- OCX 04-11-2025
- Dividend Yield
- WWR N/A
- OCX N/A
- EPS Growth
- WWR N/A
- OCX N/A
- EPS
- WWR N/A
- OCX N/A
- Revenue
- WWR N/A
- OCX $709,000.00
- Revenue This Year
- WWR N/A
- OCX N/A
- Revenue Next Year
- WWR N/A
- OCX $106.34
- P/E Ratio
- WWR N/A
- OCX N/A
- Revenue Growth
- WWR N/A
- OCX N/A
- 52 Week Low
- WWR $0.40
- OCX $1.92
- 52 Week High
- WWR $1.32
- OCX $4.75
- Technical
- Relative Strength Index (RSI)
- WWR 36.63
- OCX 82.77
- Support Level
- WWR $0.56
- OCX $3.60
- Resistance Level
- WWR $0.88
- OCX $3.95
- Average True Range (ATR)
- WWR 0.07
- OCX 0.41
- MACD
- WWR -0.02
- OCX 0.15
- Stochastic Oscillator
- WWR 18.75
- OCX 72.83
About WWR Westwater Resources Inc.
Westwater Resources Inc focused on developing battery-grade natural graphite materials. The company is having one project which is the Westwater's coosa project which is currently used for the mining and extraction of graphite.
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.